Sarepta Therapeutics Inc (NASDAQ:SRPT)

CAPS Rating: 2 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Results 1 - 20 of 51 : 1 2 3 Next »

Recs

0
Member Avatar TSIF (99.96) Submitted: 4/21/2014 3:52:47 PM : Underperform Start Price: $37.64 SRPT Score: -0.88

An early FDA review..a late FDA review...how about an "average' FDA review after all the appropriate trials are done and the data analyzed....wouldn't that be a novel idea? I do understand how some might want an early review based on the early data Sarepta Therapeutics released. $4 to $44 in 2012 was pretty lofty on such limited and ealry data, but the subsequent spikes to $40, $45, $50 were all wiped out when Sarepta was told to get in line with everyone else and do all the trials. I do hope that those with Muscular Dystrophy can be included in trials and get early access. I just don't believe that the pop to $37 today on news that the FDA is giving them testing guidelines means the FDA is advocating an early approval....Sarepta interprets it to mean they can file as early as the end of this year.

Trying to file on 12 test candidates last year really entergized the speculators. Shorts, however, continued to pile on when this dropped back sharply in November. Shorting to the level of 40% is asking for a squeeze and that's what today's "average" news generated.

Not shorting Sarepta's eteplirsen's potential or eventual FDA date.....down thumbing 40% greedy shorts who have helped to carry this up 50% today. Short term down thumb. Could, might, accelerated, will determine how long I hold.

Recs

0
Member Avatar Redbeagle (< 20) Submitted: 3/17/2014 12:07:55 PM : Outperform Start Price: $27.23 SRPT Score: +39.41

Good drug pipeline

Recs

0
Member Avatar mulledover (83.52) Submitted: 3/15/2014 11:59:06 AM : Outperform Start Price: $27.38 SRPT Score: +38.27

Phase ii results in duchenne prove their capabilities although this will likely take 2-3 years for further trials. However it's their RNA platform that makes this an interesting company for antiviral drugs for infectious diseases

Recs

0
Member Avatar manirg (52.54) Submitted: 1/27/2014 12:41:25 PM : Outperform Start Price: $23.28 SRPT Score: +58.34

Its drug is only the treatment for DMD. FDA is likely to approve it sooner or later. Hugh long term potential.

Recs

0
Member Avatar baileysmom (< 20) Submitted: 1/26/2014 8:08:50 PM : Outperform Start Price: $24.65 SRPT Score: +50.03

The only game in town when it comes to Duchenne Muscular Dystophy.

Recs

0
Member Avatar ferrariedgardo (37.17) Submitted: 1/16/2014 6:57:41 PM : Outperform Start Price: $27.37 SRPT Score: +37.51

DMD trial going well

Recs

1
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:56:09 PM : Underperform Start Price: $32.49 SRPT Score: -4.77

Short. Biopharma. Sells more stock than has revenues. Revs declining too.

Recs

3
Member Avatar EllenBrandtPhD (< 20) Submitted: 8/17/2013 2:58:48 PM : Outperform Start Price: $32.59 SRPT Score: +3.64

This is a terrifying stock, because its moves tend to be so dramatic.

If you calculate its next Big Turn correctly, either on the downside or the upside, you can make out like a bandit.

The technical picture could hardly have been worse prior to Friday's big up day, but there were many hints something was brewing. It came in the form of a key analyst upgrade and a new Propaganda push beginning Friday.

I think it may continue and that the next Big Turn - Propaganda leading Technicals - may be here.

Recs

3
Member Avatar TMFBiologyFool (98.63) Submitted: 7/24/2013 4:31:02 PM : Outperform Start Price: $37.00 SRPT Score: -8.44

Over punished on delay of FDA decision about surrogate endpoint. Should trend back up as we get closer to FDA decision.

Recs

1
Member Avatar Momentum21 (97.26) Submitted: 7/24/2013 11:34:22 AM : Outperform Start Price: $39.73 SRPT Score: -15.04

sold a little off at 46, back in at 39.99. Too many seem to like this ticker for my taste but that's OK...

https://twitter.com/Momentum21Fund

Recs

0
Member Avatar SUPERSTOCKS007 (< 20) Submitted: 5/27/2013 1:39:26 PM : Outperform Start Price: $38.75 SRPT Score: -13.89

right drug at the right time

Recs

0
Member Avatar IBDContrarian (< 20) Submitted: 4/6/2013 1:51:34 PM : Underperform Start Price: $37.06 SRPT Score: +17.92

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MEDICAL 1 99 EB NO EARN

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 3/3/2013 9:34:43 PM : Outperform Start Price: $30.37 SRPT Score: +1.98

SRPT is about to breakout huge to the upside on accelerated approval status by the FDA. Initial projections of a patient population of only 300 is vastly underestimated as it is closer to 6,000.

Recs

0
Member Avatar ravikaza2 (< 20) Submitted: 3/3/2013 7:57:45 PM : Outperform Start Price: $30.37 SRPT Score: +1.98

Only new treatment for DMD

Recs

0
Member Avatar NHWeston102 (80.46) Submitted: 2/1/2013 10:27:17 AM : Outperform Start Price: $27.48 SRPT Score: +14.37

Fast track approval, followed by pruce spike, followed by a big pharma buy out!! A good company that has done a good thing and deserves all the best - as do its buyers.

Recs

0
Member Avatar BioPharmacist (< 20) Submitted: 12/12/2012 1:47:23 AM : Outperform Start Price: $25.98 SRPT Score: +16.56

Will receive the first ever FDA breakthrough designation for their lead drug.

Recs

0
Member Avatar SnarkyContrarian (59.05) Submitted: 12/7/2012 12:09:34 PM : Underperform Start Price: $26.45 SRPT Score: -12.07

Shenanigans.

Recs

0
Member Avatar topinvestorkyle (< 20) Submitted: 10/6/2012 1:25:17 PM : Underperform Start Price: $35.50 SRPT Score: +21.43

A garbage company rise

Recs

1
Member Avatar Newt805 (69.67) Submitted: 10/4/2012 4:27:06 PM : Outperform Start Price: $4.14 SRPT Score: +780.35

Is this another NVR?

Recs

0
Member Avatar campwt00global (34.30) Submitted: 9/18/2012 1:52:36 PM : Underperform Start Price: $15.76 SRPT Score: -113.92

had its run...lookout below!

Results 1 - 20 of 51 : 1 2 3 Next »

Featured Broker Partners


Advertisement